AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki ... has downgraded AstraZeneca stock from Hold to Sell, citing concerns over the company's TROP2 asset ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Shares of AstraZeneca PLC ($GB:AZN) fell by over 3% as of writing after the pharma company released an unsatisfactory outcome ...

US Senator Sanders Says Generic Drugmakers Could Sell Ozempic for ... Goal in Late-stage Trial Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal ...

Reuters reported that industry experts predict that Pfizer’s business could sell for four times ... MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung ...

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr ...